Analytical Data
-
Gene name
BTG2
- Application
-
Alternative Names
B cell translocation gene 2; BTG family member 2; Btg2; BTG2_HUMAN
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P78543
-
Expression Region
1-158aa
-
AA Sequence
MSHGKGTDML PEIAAAVGFL SSLLRTRGCV SEQRLKVFSG ALQEALTEHY KHHWFPEKPS KGSGYRCIRI NHKMDPIISR VASQIGLSQP QLHQLLPSEL TLWVDPYEVS YRIGEDGSIC VLYEEAPLAA SCGLLTCKNQ VLLGRSSPSK NYVMAVSS
-
Molecular Weight
17.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTG2 (B-cell translocation gene 2) is a member of the BTG family of proteins, which are known for their roles in regulating cell cycle progression, differentiation, and apoptosis. Research on BTG2 has gained momentum due to its potential implications in cancer biology and other diseases. Specifically, BTG2 functions as a tumor suppressor, inhibiting cell proliferation and promoting apoptosis in various cancer types, including breast and colorectal cancers. Its expression is often downregulated in cancerous tissues, which correlates with poor prognosis and aggressive tumor behavior. Recombination and expression studies of BTG2 have been pivotal in elucidating its molecular mechanisms, involving the regulation of genes associated with cell growth and survival. Moreover, BTG2's interactions with other signaling pathways, such as the p53 tumor suppressor pathway, underscore its importance in maintaining cellular homeostasis. Understanding the structure and function of recombinantly expressed BTG2 can provide insights into its role in tumorigenesis and may reveal potential therapeutic targets for cancer treatment. Additionally, the study of BTG2’s role in cellular response to stress and differentiation emphasizes its relevance beyond cancer, potentially contributing to the understanding of neurodegenerative diseases and developmental processes. Overall, the investigation of BTG2 recombinant proteins offers a promising avenue for advancing our knowledge of its biological functions and therapeutic applications.
